Non-steroidal Anti-inflammatory Drugs

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are a class of medications used to reduce inflammation, pain, and fever by inhibiting the cyclooxygenase (COX) enzymes. According to the United States Pharmacopeia (USP) and European Pharmacopoeia (EP), NSAIDs include drugs like ibuprofen, naproxen, and aspirin. In the context of enterprise risk management, NSAIDs are classified as active pharmaceutical ingredients (APIs) requiring rigorous quality control under ICH Q9 principles. Unlike corticosteroids, they do not contain steroid hormones but pose risks like gastrointestinal bleeding or renal toxicity, necessitating stringent risk-adjusted manufacturing processes. Companies must ensure compliance with both local regulations, such as Taiwan's Pharmaceutical Safety and Quality Management Act, and international standards like FDA or EMA guidelines to mitigate product liability risks.

In practice, NSAID risk management involves three critical steps. First, establish Quality-by-Design (QbD)-based specifications, ensuring purity and potency levels meet USP/EP monographs. Second, implement rigorous analytical testing using HPLC-MS/MS or similar-high-sensitivity methods to detect impurities and degradation products, as required by ICH Q3B. Third, perform supplier-level risk-adjusted sourcing to prevent contaminated raw materials from entering the production line. For example, a pharmaceutical manufacturer implementing these steps might see a 30% reduction in out-of-specification (OOS) incidents within the first year. These measures directly impact the company's ability to pass regulatory audits and maintain market-leading quality standards.

Taiwanese enterprises typically face three challenges: regulatory complexity, technical resource constraints, and supply chain transparency. The first challenge involves the evolving requirements of the Taiwan Food and Drug Administration (TFDA), which requires detailed risk-adjusted documentation for each batch. The second is the high cost of analytical equipment needed for impurity-level testing; companies can overcome this by partnering with certified third-party labs initially. The third challenge is the lack of digital traceability in traditional manufacturing. The solution is to invest in GRP-compliant Enterprise Resource Planning (ERP) systems. A phased approach—starting with a 90-day pilot program—is recommended to ensure sustainable compliance and ROI.

Winners Consulting Services Co., Ltd. specializes in Non-steroidal Anti-inflammatory Drugs related regulatory and risk management for Taiwan enterprises, delivering compliant management systems within 90 days. We have assisted over 100 companies in achieving compliance with international standards. Request a free mechanism diagnosis at: https://winners.com.tw/contact